Because EGFR inhibition can downregulate HIF-1α expression in tumor cells and decrease VEGF secretion, we hypothesized that erlotinib treatment would indirectly lead to vascular normalization and decrease tumor hypoxia. This evidence concerns the gene VEGFA and neoplasm.